A Systematic Review of National Drug Policy in Seventeen Countries_Chinese Journal of Evidence-Based Medicine

Authors：

1. Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China;2. Panzhihua College, Panzhihua, 617000, Sichuan Province, China;

Corresponding author：

Keywords：

National drug policy; Rational use of drugs; Selection of essential drugs

DOI：

10.7507/1672-2531.20090127

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives 　To analyze the development and implementation of the national drug policy in order to provide decision-making for the establishment of the Chinese national drug policy.
Methods 　Nineteen electronic databases, the WHO, the World Bank, and governmental websites were included in this study. A pre-designed data extraction form was used to collect information. The data were analyzed and described by a pre-designed analytic framework.
Result 　A total of 182 studies were included in this review. The main points of common concern in the national drug policy were: drug regulation and quality assurance, rational use of drugs, drug supply, the selection of essential drugs, human resource development and training, traditional medicine, drug financing and affordability, drug research, monitoring and assessment of the nation drug policy, technical cooperation, and the national pharmaceutical industry. The selection of essential drugs, quality assurance, supply, pricing, and supply of traditional medicine were gradually carried out in China. Pharmaceutical research, monitoring and evaluation, as well as the development of pharmaceutical industry and technical cooperation within it should be further strengthened.
Conclusion 　China should establish related organizations and working procedures; speed up the implementation of the legislation of national drug policy; integrate the mechanism of essential drugs selection and supply system; regulate the order of medicine production and regulation; establish scientific and reasonable pricing mechanisms for drugs and assessment systems; strengthen the monitoring and evaluation of national drug policy and update and improve the national drug policy.

Citation： WANG Li,YU Jiajie,ZHOU Bangmin,LI Youping,CHENG Lan,YUAN Qiang,LI Ling,CHEN Qunfei,GAO Zhan,CUI Xiaohua. A Systematic Review of National Drug Policy in Seventeen Countries. Chinese Journal of Evidence-Based Medicine, 2009, 09(7): 715-729. doi: 10.7507/1672-2531.20090127 Copy

1.	File/qumresearch.pdf, 2008.12.
2.	File/augudddc.pdf, 2008.12.
3.	File/qumchildren.pdf, 2008.12.
4.	File/qumresearch.pdf, 2008.12.
5.	File/nmp2000.pdf, 2008.12.
6.	WHO. How to develop and implement a national drug policy. http://whqlibdoc.who.int/hq/2002/WHO_EDM_TRM_2002.1_chi.pdf.2008.12.
7.	WHO. WHO Medicines Strategy: 2004-2007, Countries at the core. http://www.who.int/medicinedocs/collect/medicinedocs/pdf/s5416e/s5416e.pdf. 2008.12.
8.	覃正碧, 汪志宏, 程刚. 国家基本药物制度的现状及其完善对策探讨. 中国药房, 2008, 19(14): 1041-1044.
9.	Unknown, 2009年全国卫生会议工作召开, 陈竺: 做好六项工作. http://www.gov.cn/gzdt/2009-01/08/content_1199449.htm. 2009.1.
10.	Zweygarth M, Summers RS. A national database for essential drugs in South Africa. Pharm World Sci, 2000, 22(3): 116-117.
11.	Tomson G, Paphassarang C, Jonsson K, et al. Decision-makers and the usefulness of research evidence in policy implementation-A case study from Lao PDR. Soc Sci Med, 2005, 61(6): 1291-1299.
12.	Stenson B, Tomson G, Syhakhang L. Pharmaceutical regulation in context: the case of Lao People’s Democratic Republic. Health Policy Plan, 1997, 12(4): 329-340.
13.	Paphassarang C, Wahlstrom R, Phoummalaysith B, et al. Building the National Drug Policy on evidence: A cross sectional study on assessing implementation in Lao PDR. Southeast Asian Journal of Tropical Medicine & Public Health, 2002, 33(3): 647-653.
14.	Chaulagai CN. Community financing for essential drugs in Nepal. World Health Forum, 1995, 16(1): 92-94.
15.	Scott DL, Alder S, Usui E, et al. Orphan drug programs/policies in Australia, Japan, and Canada. Drug Information Journal, 2001, 35(1): 1-16.
16.	Tett SE. A perspective on Australia’s National Medicines Policy. Can J Clin Pharmacol, 2004, 11(1): 28-38.
17.	Doran E, Alexander Henry D. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia. J Public Health Policy, 2008, 29(1): 106-120.
18.	Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc Sci Med, 1997, 45(4): 563-581.
19.	Lofgren H, Boer Rd. Pharmaceuticals in Australia: developments in regulation and governance. Soc Sci Med, 2004, 58(12): 2397-2407.
20.	Morgan S, McMahon M, Greyson D. Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia. Health Policy, 2008, 87(2): 133-145.
21.	Louis WJ. Conflict over drug policy in Australia. BMJ, 1989, 298(6672): 472-473.
22.	Henry DA, Hill SR, Harris A. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA, 2005, 294(20): 2630-2632.
23.	Duckett SJ. Drug policy down under: Australia’s Pharmaceutical Benefits Scheme. Health Care Finan Rev, 2004, 25(3): 55-67.
24.	Roughead EE, Monteith GR, Harvey KJ, et al. Evaluating Australia’s National Medicines Policy using geographical mapping. Intern Med J, 2002, 32(3): 66-71.
25.	Weerasuriya K. Essential drugs and registration of pharmaceuticals: the Sri Lankan experience. Bull World Health Organ, 1993, 71(2): 229-35.
26.	Bossert TJ, Bowser DM, Amenyah JK. Is decentralization good for logistics systems? Evidence on essential medicine logistics in Ghana and Guatemala. Health Policy Plan, 2007, 22(2): 73-82.
27.	Khan I. What action for rational drug use? World Health Forum, 1997, 18(1): 83-86.
28.	Anokbonggo WW, Ogwal-Okeng JW, Obua C, et al. Impact of decentralization on health services in Uganda: a look at facility utilization, prescribing and availability of essential drugs. East Afr Med J, 2004, Suppl: S2-7.
29.	Chetley A. Bangladesh: Changes to drug policy. Lancet, 1992, 340(8830): 1280-1281.
30.	Chetley A. Bangladesh: Delays for revised drug policy. Lancet, 1993, 341: 622-845.
31.	Islam MS. Therapeutic drug use in Bangladesh: policy versus practice. Indian J Med Ethics, 2008, 5(1): 24-25.
32.	Mirza Z. Islamabad - Non-emergence of Pakistan’s national drug policy. Lancet, 1996, 348(9020): 119.
33.	Anis AH. Pharmaceutical policies in Canada: another example of federal-provincial discord. Canadian Medical Association Journal, 2000, 162(4): 523-526.
34.	Angus DE, Karpetz HM. Pharmaceutical policies in Canada - Issues and challenges. Pharmacoeconomics, 1998, 14: 81-96.
35.	Hollis A, Ibbott P. How parallel trade affects drug policies and prices in Canada and the United States. Am J Law Med, 2006, 32(2-3): 193-217.
36.	Al-Sukhni M, Ballantyne P. Pharmaceutical-related strategies for health care reform in Canada: Federal party principles, priorities, and actions 2004-2006. Canadian Pharmacists Journal, 2007, 140(1): 38-45.
37.	Lexchin J. After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics. Health Policy, 1997, 40(1): 69-80.
38.	Farrell J, Ries NM, Boon H. Pharmacists and natural health products: A systematic analysis of professional responsibilities in Canada. Pharmacy Practice, 2008, 6(1): 33-42.
39.	Lexchin J. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. Health Policy, 2006, 79(2-3): 214-220.
40.	Anis AH, Wen Q. Price regulation of pharmaceuticals in Canada. J Health Econ, 1998, 17(1): 21-38.
41.	LeLorier J, Rawson NSB. Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand. Canadian Journal of Cardiology, 2007, 23(9): 711-718.
42.	Cheung RY, Cohen JC, Illingworth P. Orphan drug policies: implications for the United States, Canada, and developing countries. Health Law J, 2004, 12: 183-200.
43.	Saleh K, Ibrahim MIM. Are essential medicines in Malaysia accessible, affordable and available? Pharm World Sc, 2005, 27(6): 442-446.
44.	Kotwani A, Ewen M, Dey D, et al. Prices & availability of common medicines at six sites in India using a standard methodology. Indian J Med Res, 2007, 125(5): 645-654.
45.	Shah MB, Patel AS. Drug price control in India - An overview. Journal of Pharmaceutical Finance, Economics and Policy, 2003, 12(2): 123-131.
46.	Yang J. Essential drugs in China. World Health Forum, 1986, 7(1): 82-83.
47.	Sun Q, Santoro MA, Meng QY, et al. Pharmaceutical policy in China. Health Affairs, 2008, 27(4): 1042-1050.
48.	Yin H. Regulations and procedures for new drug evaluation and approval in China. Human Gene Therapy, 2006, 17(10): 970-974.
49.	杨军华, 张新平. 促进合理用药的国际经验与启示. 中国卫生经济, 2005, 24(6): 53-57.
50.	符策慧. 国家推行基本药物制度. 中国医疗前沿, 2007, (7): 18.
51.	江滨, 鄢尤奇, 史录文. 近年来我国药品监管政策分析. 中国药事, 2005, 19(3): 148-150.
52.	车明凤, 韩白石. 我国颁布实施《国家基本药物目录》的概况. 中国药事, 2000, 14(1): 19-21.
53.	许凤奎. 我国基本药物遴选工作概况. 中国医院管理, 1997, 17(4): 23-24.
54.	张震巍, 陈飞虎. 我国制订与实施《国家基本药物目录》的进展. 西部药学, 2004, 1(1): 12-16.
55.	陈卓蕾, 陈文, 蒋虹丽, 等. 医药费用控制相关政策分析(三)——药品费用控制政策. 中国卫生资源. 2007, (04): 76-79.
56.	钱丽萍, 刘佳, 张新平. 中印基本药物和合理用药政策比较. 中国卫生事业管理, 2003, 19(6): 381-383.
57.	An Act Regulating the Practice of Pharmacy. Senate and House of Representative of the Philippines. http://www.doh.gov.ph/ra/ra5921, 2008.12.
58.	Food, Drug, and Cosmetic Act, Senate and House of Representative of the Philippines. http://www.bfad.gov.ph/, 2008.
59.	National Health Insurance Act of 1995, government of Philippines. http://www.doh.gov.ph/node/154/pdf, 2008.12.
60.	Price Act, Congress Of Philipplines., http://www.bfad.gov.ph/, 2008.12.
61.	Badoy TJ, Implementing the Essential Drugs List the Philippine Experience. http://www.doh.gov.ph/files/ao2006-0018.pdf.2008.12.
62.	The Generics Act of 1988, Congress Of Philipplines. http://www.bfad.gov.ph/, 2008.12.
63.	Special Law on Counterfeit Drugs, Congress Of Philipplines. http://www.bfad.gov.ph/, 2008.12.
64.	Traditional & Alternative Medicine Act of 1997, Congress Of Philipplines. http://www.doh.gov.ph/node/143/pdf, 2008.12.
65.	Universally Accessible Cheaper and Quality Medicines Act of 2008, Congress Of Philipplines. http://www.doh.gov.ph/ra/cheaper_drugs, 2008.12.
66.	General Regulations for the Enforcement of the Food, Drug & Cosmetic, Department Of Health Office Of The Secretary. http://www.bfad.gov.ph/AO/ao%2061%20s%201968.pdf, 2008.12.
67.	Guidelines on the Pilot Implementation of the Electronic Essential Drug Price Monitoring(e-EDPMS), Office Of The Senate, http://www.doh.gov.ph/files/ao2008-0014_0.pdf, 2008.12.
68.	Guidelines Institutionalizing and Strengthening the Essential Drug Price Monitoring System(EDPMS), Office Of The Senate. http://www.bfad.gov.ph/AO/ao2006-0009_doh.pdf, 2006.
69.	Reporting Adverse Drug Reactions In South Africa, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=17&Desc=Guidelines%20-%20Human%20Medicines, 2008.12.
70.	Draft Policy on African Traditional Medicine for South Africa, National Ethics Committee for African Traditional Medicine. Medicines Control Council. http://www.doh.gov.za/, 2008.12.
71.	General Regulations Made In Terms Of The Medicines And Related Substances Act, 1965 (Act No. 101 Of 1965), As Amended, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=27&Desc=Acts%20and%20Regulations, 2008.12.
72.	Medicines and Related Substances Act, 1965, Government Gazette, http://www.mccza.com/showdocument.asp?Cat=27&Desc=Acts%20and%20Regulations, 2008.
73.	Medicines and Related Substances Control Amendment Bill, 1997. http://www.hst.org.za/pphc/Phila/medbill.htm, 2008.12.
74.	Pharmacy Amendment Act, No.6 of 1995. Office Of The President, http://www.doh.gov.za/docs/pharmis-f.html, 2008.12.
75.	Pharmacy Amendment Act, No.88 of 1997. Office Of The President, http://www.doh.gov.za/docs/pharmis-f.html, 2008.12.
76.	Pharmacy Amendment Act, No. 1 of 2000, Office Of The President, http://www.doh.gov.za/docs/pharmis-f.html, 2008.12.
77.	Fees Payable To The Registrar, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=2, 2008.12.
78.	Andy Gray. Drug Pricing, http://www.hst.org.za/uploads/files/drugs.p, 2008.12.
79.	Guide To Good Manufacturing Practice For Medicines In South Africa, Medicines Control Council, http://www.mccza.com/showdocument.asp?Cat=1, 2008.12.
80.	Guideline For The Direct Transmission Of Fees Payable To The Registrar Of Medicines, Medicines Control Council, http://www.mccza.com/showdocument.asp?Cat=2, 2008.12.
81.	Guidelines On Inspections Involving The GMP Inspectors, Medicines Control Council, http://www.mccza.com/showdocument.asp?Cat=1, 2008.12.
82.	The impact of rationalised pharmaceutical procurement and distribution and of the essential drugs programme implementation, MEDUNSA School of Pharmacy. http://www.hst.org.za/uploads/files/drgmx_n. 2008.12.
83.	Implementation Of The Post-Registration Amendments Guideline, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=17&Desc=Guidelines%20-%20Human%20Medicines, 2008.12.
84.	Package Inserts For Human Medicines, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=17&Desc=Guidelines%20-%20Human%20Medicines, 2008.
85.	南非药品信息体系, http://www.doh.gov.za/department/clus_pharma.html, 2008.12.
86.	Bhutan Medicines Rules & Regulations 2005. Kingdom of Bhutan. http://www.health.gov.bt/downloads/EnglishRegulations.pdf. 2005.
87.	Guidelines for application for Registration of Medicinal Products 2006(DRA). Drug regulatory authority, http://www.health.gov.bt/downloads/draRegisGuidenew.pdf, 2008.12.
88.	The Medicines Act Of The Kingdom Of Bhutan 2003. http://www.health.gov.bt/downloads/EnglishMedicinesAct.pdf, 2008.12.
89.	Procurement Manual rules and procedures 2007 . Royal Government of Bhutan Ministry of Finance, http://www.health.gov.bt/downloads/procurementmanual.pdf, 2008.12.
90.	Bell JF. Guideline On Continuing Medical Education, ministry of health http://www.health.gov.bt/downloads/CMEguideline07.pdf.
91.	Drugs, vaccines and equipment division, procurement procedures. ministry of health, http://www.health.gov.bt/dms/dved/procurementProc.pdf, 2008.12.
92.	Drug Act. 2035 (1978). http://www.dda.gov.np/drugact.php, 2008.12.
93.	Guidelines on Ethical Promotion of Medicine, 2007. http://www.dda.gov.np/guidance.php, 2008.12.
94.	Guidelines on Labelling. Department of Drug Administration. http://www.dda.gov.np/guidance.php, 2008.12.
95.	National Good Pharmacy Practice Guidelines. Nepal Pharmacy Council. http://www.dda.gov.np/guidlines/national_gp, 2008.12.
96.	Bijulibazar, Kathmandu. Report On Consumption And Quantification Of Modern Drugs For Human Use In Nepal. Department of Drug Administration. http://www.dda.gov.np/quantification/quanti_2001.pdf, 2008.12.
97.	Bijulibazar, Kathmandu. Report On Quantification Of Drug Consumption In Nepal. Department of Drug Administration. http://www.dda.gov.np/quantification/quanti_2006.pdf, 2008.12.
98.	Guidelines for Drug Donations. Government of Nepal. http://www.dda.gov.np/guidlines/other_guidence.pdf, 2008.12.
99.	Rational Drug Use. The Directorate General Of Pharmaceutical Affairs And Drug Control. http://www.moh.gov.om/pharma/rdupeng.pdf, 2008.12.
100.	Quality Use Of Medicines-– A Decade Of Research,Development And Service Activity. Pharmaceutical Health and Rational use of Medicines Committee. http://www.health.gov.au/internet/main/publishing.nsf/Content/AEC9F819EA0345F7CA256F1800468F04/.
101.	Australian guidelines for drug donations to developing countries. Australian Pharmaceutical Advisory Council. http://www.health.gov.au/internet/main/publishing.nsf/Content/035470C60EE4E52FCA256F1800468850/.
102.	The Quality Use of Medicines and Children. Pharmaceutical Health And Rational use of Medicines (PHARM) Committee. http://www.health.gov.au/internet/main/publishing.nsf/Content/55E55D36126F25F7CA2573FC00062A82/.
103.	The Therapeutic Goods Administration’s risk management approach to the regulation of therapeutic goods. Department Of Health And Ageing Therapeutic Goods Administration. http://www.tga.gov.au/about/tgariskmnt.pdf, 2008.12.
104.	Policies, Procedures And Methods Used In The Pricing Of Pharmaceutical Products. Pharmaceutical Benefits Pricing Authority. Http://Www.Health.Gov.Au/, 2008.12.
105.	The National Strategy for Quality Use of Medicines. Pharmaceutical Health And Rational use of Medicines (PHARM) Committee. http://www.health.gov.au/internet/main/publishing.nsf/Content/AEC9F819EA0345F7CA256F1800468F04/.
106.	The Expectations, the Reality And The Burden Of Drug Donations. Ministy of Healthcare & Nutrition. http://www.health.gov.lk/msd/Page1-9MSD.pdf, 2008.12.
107.	Dr Nihal Jayathilaka. Improving access to affordable essential drugs. Ministry of health.http://www.wpro.who.int/NR/rdonlyres/1A29C051-DE36-4521-AB7B-812E8274456D/0/03SriLanka2A1.pdf. 2008.12.
108.	Sri Lanka National Health System Profile. http://www.health.gov.lk/, 2008.12.
109.	F. K. HLORTSI-AKAKPO, Traditional Medicine. Traditional Medicine Practice Council, http://www.moh-ghana.org/moh/aboutus/policies.asp, 2008.
110.	Drugs (Licensing, Registering And Advertising) Rules, 1976. the Federal Government, http://www.dcomoh.gov.pk/regulations/drugrules5.php, 2008.12.
111.	The Drugs Act. http://www.dcomoh.gov.pk/regulations/pharmacyact1967.php, 2008.12.
112.	Guidelines For cGMP Inspection of Biological Drugs. Ministry of Health. http://www.dcomoh.gov.pk/, 2008.12.
113.	Guildline For Registration of Biological Drugs. Ministry of Health. http://www.dcomoh.gov.pk/, 2008.12.
114.	Pakistan- An Introduction. http://www.dcomoh.gov.pk/, 2008.12.
115.	The Drugs (Labelling and Packing) Rules, http://www.dcomoh.gov.pk/, 2008.12.
116.	Problem of Irrational Drug Use. Pakistan drug update. http://www.dcomoh.gov.pk/, 2008.12.
117.	Mohammad Saidul Islam. How Complementary and Alternative Medicine (CAM) is promoted in Bangladesh. The Internet Journal of Alternative Medicine, 2008, 5(2): 1450-1458.
118.	The Drugs (Control) Ordinance, http://www.mohfw.gov.bd/, 1982.
119.	Drug Registration Procedure And Requirements In Bangladesh. http://www.mohfw.gov.bd/drug%20registration.htm, 2008.12.
120.	Drug Act, Government of Bangladesh. 2008.12.
121.	Code Of Pharmaceutical Marketing Practices. Drugs Administration Ministry of Health And Family Welfare, http://www.mohfw.gov.bd/, 2008.12.
122.	Regulations, Policies and Standards in Pharmaceutical Industry. Directorate of Drugs Administration, http://www.mohfw.gov.bd/, 2008.12.
123.	The Bengal Drugs Rules, Government of East Bengal Health and LocalSelf-GovernmentDepartment. 2008.12.
124.	Bruce Carleton. Post-Marketing Pharmacosurveillance In Canada. http://www.hc-sc.gc.ca/dhp-mps/index-eng.php, 2008.12.
125.	Wendy Kennedy. The Health Transition Fund (Pharmaceutical Issues). http://www.hc-sc.gc.ca, 2008.12.
126.	A Comparison of Pharmaceutical Reaseach and Development Spending. Patented Medicine Prices Review Board, http://www.mohfw.gov.bd/, 2008.12.
127.	Access to Therapeutic Products in Canada, ministry of health. http://www.mohfw.gov.bd/, 2008.12.
128.	National Pharmaceuticals Strategy (NPS). ministry of health. http://www.mohfw.gov.bd/, 2008.12.
129.	Gary Fox, Medicines that Work for Canadians (Business Plan for a Drug Effectiveness and Safety Network). http://www.mohfw.gov.bd/, 2008.12.
130.	Traditional and Complementary Medicine. http://www.myhealth.gov.my/myhealth/eng/ubat_anda_content.jsp?lang=ubat&storymaster=1225785083091&storyid=1225785618675&sub, 2008.12.
131.	Medicines (Advertisement And Sale)Act, http://www.pharmacy.gov.my/, 2008.12.
132.	Registration of Pharmacists Act, http://www.pharmacy.gov.my, 2008.
133.	马来西亚药品管理体系, http://www.pharmacy.gov.my. 2008.12.
134.	Drug Registration Guidance Document, National Pharmaceutical Control Bureau, http://www.pharmacy.gov.my, 2008.
135.	drug policy, http://www.nppaindia.nic.in/drug_pol86/txt1.html, 2008.
136.	Drugs(Prices Control) Order. Ministry of Chemicals and Fertilizers. http://www.nppaindia.nic.in/drug_price95/txt1.html, 2008.12.
137.	Modifications in Drug Policy. http://www.nppaindianic.in/drug_pol86/modif86/mod1.html, 2008.12.
138.	Pharmaceutical Policy-2002. Prime Minister’s Advisory Council. http://www.nppaindia.nic.in/may-2002/policy-02.html, 2008.12.
139.	Dte.GHS, Central Drugs Standard Control Organization-Laws Pertaining To Manufacture And Sale Of Drugs In India, Ministry of Health and Family Welfare. http://www.cdsco.nic.in/html/law.htm.
140.	The Drugs And Cosmetics Act And Rules. Ministry of Health And Family Welfare. http://www.cdsco.nic.in/html/Copy%20of%201.%20D&CAct121.pdf, 2008.12.
141.	Price Control Order (DPCO), National Pharmaceutical Pricing Authority . http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-policies/drugs-price-control-order.html, 2008.12.
142.	Procedure for Price Fixation. National Pharmaceutical Pricing Authority, http://www.nppaindia.nic.in/may-2002/procedure-bd.html, 1 2008.12.
143.	Procedure for Pricing of Formulations. National Pharmaceutical Pricing Authority. http://www.nppaindia.nic.in/may2002/procedure-form.html, 2008.12.
144.	Central Drugs Standard Control Organization-Drugs Control Administration. Drugs Control Administration. http://www.cdsco.nic.in/html/Drugs_ContAd.html, 2008.12.
145.	中华人民共和国药品管理法, 国家食品药品监督管理局. http://www.sda.gov.cn/WS01/CL0064/23396.html, 2008.12.
146.	中华人民共和国药品管理法实施条例, 国家食品药品监督管理局. http://www.sda.gov.cn/WS01/CL0062/23395.html, 2008.12.
147.	WHO. Essential medicines: access, quality and rational use – highlights of 2000, www.who.int/mip2001/files/2158/MIP01_APR_HTP2.en.pdf, 2008.12.
148.	WHO. The WHO Essential Medicines List (EML): 30th anniversary. www.who.int/entity/medicines/events/fs/en/, 2008.12.
149.	WHO. Comparative analysis of national drug policies. www.wpro.who.int/NR/rdonlyres/F1EFC301-FD5E-4BEE-9FD7-656965FD882B/0/EDMnewsletterECACPWHOyear2.pdf, 2008.12.
150.	WHO Regional Office of the Western Pacific. Drug Price Control Bills in the Philippines/ Ethical Practices in Medicines Regulation and Procurement. Essential drug & medicine policy, 2008.12.
151.	WHO. The Role of Education in the Rational Use of Medicines. www.wpro.who.int/NR/rdonlyres/8B64881B-DE1A-4A31-B670-B87265FBBB7F/0/EDMP_Dec04.pdf, 2008.12.
152.	WHO. Malaysia formulates national medicines policy. Essential drug & medicine policy, 2002, 1(1):537-542.
153.	WHO. Strengthening ADR Monitoring in the Philippines. Essential drug & medicine policy, 2003, 2(1): 765-769.
154.	WHO. Computerized Drug Registration- The Lao People’s Democratic Republic/ Monitoring and Assessing the Pharmaceutical Situation in Malaysia. Essential drug & medicine policy, 2002, 1(2): 253-258.
155.	WHO. Assessment of the Distribution Practices of Medicines in thePhilippines. Essential drug & medicine policy, 2004, 3(2): 753-760.
156.	WHO. Philippines Chosen as a MeTA Pilot Country/ Cheaper Medicines Bill in the Philippines/ Philippines Develops Quality Seal System for Pharmaceuticals. Essential drug & medicine policy, 2007, 7(3): 341-346.
157.	WHO. Medicines Price Monitoring in Malaysia. Essential drug & medicine policy, 2006, 5(1): 445-448.
158.	WHO. Annual Report 2001:Essential Drugs and Medicines Policy: Extending the Evidence Base. www.who.int/mip2002/index.pl%3Fid=2304&isa=Item&field_name=item_attachment_file&op=download_file, 2008.12.
159.	WHO. How to develop a national formulary based on the WHO model formulary. www.who.int/emlib/docs/National_MF_Manual2004-8.pdf, 2008.12.
160.	WHO. Medicine Prices in Ghana: A comparative study of Public, Private and Mission sector medicine prices. www.afro.who.int/dsd/survey_reports/ghana.pdf, 2008.12.
161.	WHO. Biregional Workshop On Promoting Ethical Practices In Medicines Registration And Procurement., whqlibdoc.who.int/wpro/2006/RS_2005_GE_12_MAA.pdf, 2008.12.
162.	WHO. Essential drugs and other supplies. http://www.searo.who.int/EN/Section313/Section1515_6124.htm, 2008.12.
163.	WHO. rational use of medicines in the lao people’s democratic republic strategy/ combating counterfeit drugs in the lao people’s democratic republic. Essential drug & medicine policy, 2003, 2(2): 752-756.
164.	WHO. Drug Supply Management in the Context of IMCI（Drug Supply and Management Training in South Africa. whqlibdoc. who.int/searo/2001/SEA_Drugs_152.pdf, 2008.12.
165.	WHO. Rational Drug Use (RDU). www.emro.who.int/Publications/EMHJ/1305/article25.htm, 2008.12.
166.	WHO. Use of the WHO certification scheme on the quality of pharmaceutical products moving in international commerce. whqlibdoc.who.int/hq/1994/WHO_DAP_94.21.pdf, 2008.12.
167.	WHO. Uganda pharmaceutical sector baseline survey. whqlibdoc.who.int/hq/2002/a87427_eng.pdf, 2008.12.
168.	WHO. An assessment of the pharmaceutical sector. whqlibdoc.who.int/hq/2002/a87429_eng.pdf, 2008.12.
169.	WHO. Effective drug regulation. www.who.int/entity/medicines/areas/rational_use/startingstrengdrugbulletin.pdf, 2008.12.
170.	WHO. Reports World Medicines Situation. whqlibdoc.who.int/hq/1994/WHO_DAP_94.21.pdf, 2008.12.
171.	WHO. Essential Medicines List. whqlibdoc.who.int/hq/2006/WHO_PSM_PAR_2006.5_eng.pdf, 2008.12.
172.	WHO. Successful partnership in Pakistan for rational use and management of medicines. Essential Drugs in Brief, 2003, 3(9).
173.	WHO. Access to affordable essential medicines. www.who.int/entity/medicines/mdg/MDG08ChapterEMedsEn.pdf, 2008.12.
174.	WHO. Regional Strategy For Improving Access To Essential Medicines In The Western Pacific Region, 2004-2009, 2008.12.
175.	Implementing Guidelines For The Philippines NDP System. Ministry of health. http://www.doh.gov.ph/ndp_issuances, 2008.12.
176.	Lao national drug policy programme. Department for democracy and social development.http://www.globala.sida.se/sida/jsp/sida.jsp?d=118&a=2218&language=en_US, 2008.12.
177.	Oman National Drug Policy. The Directorate General Of Pharmaceutical Affairs And Drug Control. http://www.moh.gov.om/pharma/ndpeng.pdf, 2008.12.
178.	National medicine policy ( Australia ). Department of health and aging. http://www.health.gov.au/internet/main/publishing.nsf/Content/0241A32640D477CACA256F18004685E4/.
179.	National drug policy (Bhutan). Department of Medical Services Ministry of Health Royal Government of Bhutan. http://www.health.gov.bt/downloads/drugPolicy.pdf, 2008.12.
180.	National Drug Policy for South Africa. Minister of Health. http://www.doh.gov.za/docs/policy/drugsjan1996.pdf, 2008.12.
181.	National Drug Policy (Nepal). Commitment of Government Of Nepal. http://www.google.cn/search?hl=zh-CN&newwindow=1&q=National+Drug+Policy+nepal&btnG= Google+%E6%90%9C%E7%B4%A2&meta= &aq=f&oq=, 2008.12.
182.	National Medicinal Drug Policy For SriLanka, http://www.who.int/medicines/areas/policy/NMDP_SriLanka.pdf, 2008.12.
183.	National drug policy (Pakistan). Ministry of health. http://www.dcomoh.gov.pk/publications/ndp.php, 2008.12.
184.	National drug policy (Uganda). The National Drug Authority, http://www.nda.or.ug/index.php, 2008.12.
185.	National Medicine Policy (Afghanistan). Ministry of Health. http://ispb.univ-lyon1.fr/Lyon%20Kaboul/politique_de_sante_en_afghanistan/rapports/Politique%20du%20m%E9dicament.pdf, 2008.12.
186.	National Pharmaceuticals Strategy ( Canada ). Health Canada, http://www.hc-sc.gc.ca/hcs-sss/alt_formats/hpb-dgps/pdf/pubs/2006-nps-snpp/2006-nps-snpp-eng.pdf, 2008.12.
187.	Ghana National Drug Policy. Ministry of Health (GNDP) Ghana, http://www.who.int/countries/gha/publications/Ghana_National_DrugPolicy_2nd_Edition.pdf, 2008.12.
188.	National medicines policy of Malaysia. Ministry of health Malaysia. http://www.pharmacy.gov.my/, 2008.12.
189.	National drug policy (Bangladesh) . Ministry Of Health And Family Welfare . http://www.ailonline.net/skf_new/images/files/.
190.	National_Drug_Policy_May_05.pdf, 2008.12.
191.	张新平,李少丽. 药物政策学. 北京: 科学出版社, 2003.

1. File/qumresearch.pdf, 2008.12.
2. File/augudddc.pdf, 2008.12.
3. File/qumchildren.pdf, 2008.12.
4. File/qumresearch.pdf, 2008.12.
5. File/nmp2000.pdf, 2008.12.
6. WHO. How to develop and implement a national drug policy. http://whqlibdoc.who.int/hq/2002/WHO_EDM_TRM_2002.1_chi.pdf.2008.12.
7. WHO. WHO Medicines Strategy: 2004-2007, Countries at the core. http://www.who.int/medicinedocs/collect/medicinedocs/pdf/s5416e/s5416e.pdf. 2008.12.
8. 覃正碧, 汪志宏, 程刚. 国家基本药物制度的现状及其完善对策探讨. 中国药房, 2008, 19(14): 1041-1044.
9. Unknown, 2009年全国卫生会议工作召开, 陈竺: 做好六项工作. http://www.gov.cn/gzdt/2009-01/08/content_1199449.htm. 2009.1.
10. Zweygarth M, Summers RS. A national database for essential drugs in South Africa. Pharm World Sci, 2000, 22(3): 116-117.
11. Tomson G, Paphassarang C, Jonsson K, et al. Decision-makers and the usefulness of research evidence in policy implementation-A case study from Lao PDR. Soc Sci Med, 2005, 61(6): 1291-1299.
12. Stenson B, Tomson G, Syhakhang L. Pharmaceutical regulation in context: the case of Lao People’s Democratic Republic. Health Policy Plan, 1997, 12(4): 329-340.
13. Paphassarang C, Wahlstrom R, Phoummalaysith B, et al. Building the National Drug Policy on evidence: A cross sectional study on assessing implementation in Lao PDR. Southeast Asian Journal of Tropical Medicine & Public Health, 2002, 33(3): 647-653.
14. Chaulagai CN. Community financing for essential drugs in Nepal. World Health Forum, 1995, 16(1): 92-94.
15. Scott DL, Alder S, Usui E, et al. Orphan drug programs/policies in Australia, Japan, and Canada. Drug Information Journal, 2001, 35(1): 1-16.
16. Tett SE. A perspective on Australia’s National Medicines Policy. Can J Clin Pharmacol, 2004, 11(1): 28-38.
17. Doran E, Alexander Henry D. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia. J Public Health Policy, 2008, 29(1): 106-120.
18. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc Sci Med, 1997, 45(4): 563-581.
19. Lofgren H, Boer Rd. Pharmaceuticals in Australia: developments in regulation and governance. Soc Sci Med, 2004, 58(12): 2397-2407.
20. Morgan S, McMahon M, Greyson D. Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia. Health Policy, 2008, 87(2): 133-145.
21. Louis WJ. Conflict over drug policy in Australia. BMJ, 1989, 298(6672): 472-473.
22. Henry DA, Hill SR, Harris A. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA, 2005, 294(20): 2630-2632.
23. Duckett SJ. Drug policy down under: Australia’s Pharmaceutical Benefits Scheme. Health Care Finan Rev, 2004, 25(3): 55-67.
24. Roughead EE, Monteith GR, Harvey KJ, et al. Evaluating Australia’s National Medicines Policy using geographical mapping. Intern Med J, 2002, 32(3): 66-71.
25. Weerasuriya K. Essential drugs and registration of pharmaceuticals: the Sri Lankan experience. Bull World Health Organ, 1993, 71(2): 229-35.
26. Bossert TJ, Bowser DM, Amenyah JK. Is decentralization good for logistics systems? Evidence on essential medicine logistics in Ghana and Guatemala. Health Policy Plan, 2007, 22(2): 73-82.
27. Khan I. What action for rational drug use? World Health Forum, 1997, 18(1): 83-86.
28. Anokbonggo WW, Ogwal-Okeng JW, Obua C, et al. Impact of decentralization on health services in Uganda: a look at facility utilization, prescribing and availability of essential drugs. East Afr Med J, 2004, Suppl: S2-7.
29. Chetley A. Bangladesh: Changes to drug policy. Lancet, 1992, 340(8830): 1280-1281.
30. Chetley A. Bangladesh: Delays for revised drug policy. Lancet, 1993, 341: 622-845.
31. Islam MS. Therapeutic drug use in Bangladesh: policy versus practice. Indian J Med Ethics, 2008, 5(1): 24-25.
32. Mirza Z. Islamabad - Non-emergence of Pakistan’s national drug policy. Lancet, 1996, 348(9020): 119.
33. Anis AH. Pharmaceutical policies in Canada: another example of federal-provincial discord. Canadian Medical Association Journal, 2000, 162(4): 523-526.
34. Angus DE, Karpetz HM. Pharmaceutical policies in Canada - Issues and challenges. Pharmacoeconomics, 1998, 14: 81-96.
35. Hollis A, Ibbott P. How parallel trade affects drug policies and prices in Canada and the United States. Am J Law Med, 2006, 32(2-3): 193-217.
36. Al-Sukhni M, Ballantyne P. Pharmaceutical-related strategies for health care reform in Canada: Federal party principles, priorities, and actions 2004-2006. Canadian Pharmacists Journal, 2007, 140(1): 38-45.
37. Lexchin J. After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics. Health Policy, 1997, 40(1): 69-80.
38. Farrell J, Ries NM, Boon H. Pharmacists and natural health products: A systematic analysis of professional responsibilities in Canada. Pharmacy Practice, 2008, 6(1): 33-42.
39. Lexchin J. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. Health Policy, 2006, 79(2-3): 214-220.
40. Anis AH, Wen Q. Price regulation of pharmaceuticals in Canada. J Health Econ, 1998, 17(1): 21-38.
41. LeLorier J, Rawson NSB. Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand. Canadian Journal of Cardiology, 2007, 23(9): 711-718.
42. Cheung RY, Cohen JC, Illingworth P. Orphan drug policies: implications for the United States, Canada, and developing countries. Health Law J, 2004, 12: 183-200.
43. Saleh K, Ibrahim MIM. Are essential medicines in Malaysia accessible, affordable and available? Pharm World Sc, 2005, 27(6): 442-446.
44. Kotwani A, Ewen M, Dey D, et al. Prices & availability of common medicines at six sites in India using a standard methodology. Indian J Med Res, 2007, 125(5): 645-654.
45. Shah MB, Patel AS. Drug price control in India - An overview. Journal of Pharmaceutical Finance, Economics and Policy, 2003, 12(2): 123-131.
46. Yang J. Essential drugs in China. World Health Forum, 1986, 7(1): 82-83.
47. Sun Q, Santoro MA, Meng QY, et al. Pharmaceutical policy in China. Health Affairs, 2008, 27(4): 1042-1050.
48. Yin H. Regulations and procedures for new drug evaluation and approval in China. Human Gene Therapy, 2006, 17(10): 970-974.
49. 杨军华, 张新平. 促进合理用药的国际经验与启示. 中国卫生经济, 2005, 24(6): 53-57.
50. 符策慧. 国家推行基本药物制度. 中国医疗前沿, 2007, (7): 18.
51. 江滨, 鄢尤奇, 史录文. 近年来我国药品监管政策分析. 中国药事, 2005, 19(3): 148-150.
52. 车明凤, 韩白石. 我国颁布实施《国家基本药物目录》的概况. 中国药事, 2000, 14(1): 19-21.
53. 许凤奎. 我国基本药物遴选工作概况. 中国医院管理, 1997, 17(4): 23-24.
54. 张震巍, 陈飞虎. 我国制订与实施《国家基本药物目录》的进展. 西部药学, 2004, 1(1): 12-16.
55. 陈卓蕾, 陈文, 蒋虹丽, 等. 医药费用控制相关政策分析(三)——药品费用控制政策. 中国卫生资源. 2007, (04): 76-79.
56. 钱丽萍, 刘佳, 张新平. 中印基本药物和合理用药政策比较. 中国卫生事业管理, 2003, 19(6): 381-383.
57. An Act Regulating the Practice of Pharmacy. Senate and House of Representative of the Philippines. http://www.doh.gov.ph/ra/ra5921, 2008.12.
58. Food, Drug, and Cosmetic Act, Senate and House of Representative of the Philippines. http://www.bfad.gov.ph/, 2008.
59. National Health Insurance Act of 1995, government of Philippines. http://www.doh.gov.ph/node/154/pdf, 2008.12.
60. Price Act, Congress Of Philipplines., http://www.bfad.gov.ph/, 2008.12.
61. Badoy TJ, Implementing the Essential Drugs List the Philippine Experience. http://www.doh.gov.ph/files/ao2006-0018.pdf.2008.12.
62. The Generics Act of 1988, Congress Of Philipplines. http://www.bfad.gov.ph/, 2008.12.
63. Special Law on Counterfeit Drugs, Congress Of Philipplines. http://www.bfad.gov.ph/, 2008.12.
64. Traditional & Alternative Medicine Act of 1997, Congress Of Philipplines. http://www.doh.gov.ph/node/143/pdf, 2008.12.
65. Universally Accessible Cheaper and Quality Medicines Act of 2008, Congress Of Philipplines. http://www.doh.gov.ph/ra/cheaper_drugs, 2008.12.
66. General Regulations for the Enforcement of the Food, Drug & Cosmetic, Department Of Health Office Of The Secretary. http://www.bfad.gov.ph/AO/ao%2061%20s%201968.pdf, 2008.12.
67. Guidelines on the Pilot Implementation of the Electronic Essential Drug Price Monitoring(e-EDPMS), Office Of The Senate, http://www.doh.gov.ph/files/ao2008-0014_0.pdf, 2008.12.
68. Guidelines Institutionalizing and Strengthening the Essential Drug Price Monitoring System(EDPMS), Office Of The Senate. http://www.bfad.gov.ph/AO/ao2006-0009_doh.pdf, 2006.
69. Reporting Adverse Drug Reactions In South Africa, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=17&Desc=Guidelines%20-%20Human%20Medicines, 2008.12.
70. Draft Policy on African Traditional Medicine for South Africa, National Ethics Committee for African Traditional Medicine. Medicines Control Council. http://www.doh.gov.za/, 2008.12.
71. General Regulations Made In Terms Of The Medicines And Related Substances Act, 1965 (Act No. 101 Of 1965), As Amended, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=27&Desc=Acts%20and%20Regulations, 2008.12.
72. Medicines and Related Substances Act, 1965, Government Gazette, http://www.mccza.com/showdocument.asp?Cat=27&Desc=Acts%20and%20Regulations, 2008.
73. Medicines and Related Substances Control Amendment Bill, 1997. http://www.hst.org.za/pphc/Phila/medbill.htm, 2008.12.
74. Pharmacy Amendment Act, No.6 of 1995. Office Of The President, http://www.doh.gov.za/docs/pharmis-f.html, 2008.12.
75. Pharmacy Amendment Act, No.88 of 1997. Office Of The President, http://www.doh.gov.za/docs/pharmis-f.html, 2008.12.
76. Pharmacy Amendment Act, No. 1 of 2000, Office Of The President, http://www.doh.gov.za/docs/pharmis-f.html, 2008.12.
77. Fees Payable To The Registrar, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=2, 2008.12.
78. Andy Gray. Drug Pricing, http://www.hst.org.za/uploads/files/drugs.p, 2008.12.
79. Guide To Good Manufacturing Practice For Medicines In South Africa, Medicines Control Council, http://www.mccza.com/showdocument.asp?Cat=1, 2008.12.
80. Guideline For The Direct Transmission Of Fees Payable To The Registrar Of Medicines, Medicines Control Council, http://www.mccza.com/showdocument.asp?Cat=2, 2008.12.
81. Guidelines On Inspections Involving The GMP Inspectors, Medicines Control Council, http://www.mccza.com/showdocument.asp?Cat=1, 2008.12.
82. The impact of rationalised pharmaceutical procurement and distribution and of the essential drugs programme implementation, MEDUNSA School of Pharmacy. http://www.hst.org.za/uploads/files/drgmx_n. 2008.12.
83. Implementation Of The Post-Registration Amendments Guideline, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=17&Desc=Guidelines%20-%20Human%20Medicines, 2008.12.
84. Package Inserts For Human Medicines, Medicines Control Council. http://www.mccza.com/showdocument.asp?Cat=17&Desc=Guidelines%20-%20Human%20Medicines, 2008.
85. 南非药品信息体系, http://www.doh.gov.za/department/clus_pharma.html, 2008.12.
86. Bhutan Medicines Rules & Regulations 2005. Kingdom of Bhutan. http://www.health.gov.bt/downloads/EnglishRegulations.pdf. 2005.
87. Guidelines for application for Registration of Medicinal Products 2006(DRA). Drug regulatory authority, http://www.health.gov.bt/downloads/draRegisGuidenew.pdf, 2008.12.
88. The Medicines Act Of The Kingdom Of Bhutan 2003. http://www.health.gov.bt/downloads/EnglishMedicinesAct.pdf, 2008.12.
89. Procurement Manual rules and procedures 2007 . Royal Government of Bhutan Ministry of Finance, http://www.health.gov.bt/downloads/procurementmanual.pdf, 2008.12.
90. Bell JF. Guideline On Continuing Medical Education, ministry of health http://www.health.gov.bt/downloads/CMEguideline07.pdf.
91. Drugs, vaccines and equipment division, procurement procedures. ministry of health, http://www.health.gov.bt/dms/dved/procurementProc.pdf, 2008.12.
92. Drug Act. 2035 (1978). http://www.dda.gov.np/drugact.php, 2008.12.
93. Guidelines on Ethical Promotion of Medicine, 2007. http://www.dda.gov.np/guidance.php, 2008.12.
94. Guidelines on Labelling. Department of Drug Administration. http://www.dda.gov.np/guidance.php, 2008.12.
95. National Good Pharmacy Practice Guidelines. Nepal Pharmacy Council. http://www.dda.gov.np/guidlines/national_gp, 2008.12.
96. Bijulibazar, Kathmandu. Report On Consumption And Quantification Of Modern Drugs For Human Use In Nepal. Department of Drug Administration. http://www.dda.gov.np/quantification/quanti_2001.pdf, 2008.12.
97. Bijulibazar, Kathmandu. Report On Quantification Of Drug Consumption In Nepal. Department of Drug Administration. http://www.dda.gov.np/quantification/quanti_2006.pdf, 2008.12.
98. Guidelines for Drug Donations. Government of Nepal. http://www.dda.gov.np/guidlines/other_guidence.pdf, 2008.12.
99. Rational Drug Use. The Directorate General Of Pharmaceutical Affairs And Drug Control. http://www.moh.gov.om/pharma/rdupeng.pdf, 2008.12.
100. Quality Use Of Medicines-– A Decade Of Research,Development And Service Activity. Pharmaceutical Health and Rational use of Medicines Committee. http://www.health.gov.au/internet/main/publishing.nsf/Content/AEC9F819EA0345F7CA256F1800468F04/.
101. Australian guidelines for drug donations to developing countries. Australian Pharmaceutical Advisory Council. http://www.health.gov.au/internet/main/publishing.nsf/Content/035470C60EE4E52FCA256F1800468850/.
102. The Quality Use of Medicines and Children. Pharmaceutical Health And Rational use of Medicines (PHARM) Committee. http://www.health.gov.au/internet/main/publishing.nsf/Content/55E55D36126F25F7CA2573FC00062A82/.
103. The Therapeutic Goods Administration’s risk management approach to the regulation of therapeutic goods. Department Of Health And Ageing Therapeutic Goods Administration. http://www.tga.gov.au/about/tgariskmnt.pdf, 2008.12.
104. Policies, Procedures And Methods Used In The Pricing Of Pharmaceutical Products. Pharmaceutical Benefits Pricing Authority. Http://Www.Health.Gov.Au/, 2008.12.
105. The National Strategy for Quality Use of Medicines. Pharmaceutical Health And Rational use of Medicines (PHARM) Committee. http://www.health.gov.au/internet/main/publishing.nsf/Content/AEC9F819EA0345F7CA256F1800468F04/.
106. The Expectations, the Reality And The Burden Of Drug Donations. Ministy of Healthcare & Nutrition. http://www.health.gov.lk/msd/Page1-9MSD.pdf, 2008.12.
107. Dr Nihal Jayathilaka. Improving access to affordable essential drugs. Ministry of health.http://www.wpro.who.int/NR/rdonlyres/1A29C051-DE36-4521-AB7B-812E8274456D/0/03SriLanka2A1.pdf. 2008.12.
108. Sri Lanka National Health System Profile. http://www.health.gov.lk/, 2008.12.
109. F. K. HLORTSI-AKAKPO, Traditional Medicine. Traditional Medicine Practice Council, http://www.moh-ghana.org/moh/aboutus/policies.asp, 2008.
110. Drugs (Licensing, Registering And Advertising) Rules, 1976. the Federal Government, http://www.dcomoh.gov.pk/regulations/drugrules5.php, 2008.12.
111. The Drugs Act. http://www.dcomoh.gov.pk/regulations/pharmacyact1967.php, 2008.12.
112. Guidelines For cGMP Inspection of Biological Drugs. Ministry of Health. http://www.dcomoh.gov.pk/, 2008.12.
113. Guildline For Registration of Biological Drugs. Ministry of Health. http://www.dcomoh.gov.pk/, 2008.12.
114. Pakistan- An Introduction. http://www.dcomoh.gov.pk/, 2008.12.
115. The Drugs (Labelling and Packing) Rules, http://www.dcomoh.gov.pk/, 2008.12.
116. Problem of Irrational Drug Use. Pakistan drug update. http://www.dcomoh.gov.pk/, 2008.12.
117. Mohammad Saidul Islam. How Complementary and Alternative Medicine (CAM) is promoted in Bangladesh. The Internet Journal of Alternative Medicine, 2008, 5(2): 1450-1458.
118. The Drugs (Control) Ordinance, http://www.mohfw.gov.bd/, 1982.
119. Drug Registration Procedure And Requirements In Bangladesh. http://www.mohfw.gov.bd/drug%20registration.htm, 2008.12.
120. Drug Act, Government of Bangladesh. 2008.12.
121. Code Of Pharmaceutical Marketing Practices. Drugs Administration Ministry of Health And Family Welfare, http://www.mohfw.gov.bd/, 2008.12.
122. Regulations, Policies and Standards in Pharmaceutical Industry. Directorate of Drugs Administration, http://www.mohfw.gov.bd/, 2008.12.
123. The Bengal Drugs Rules, Government of East Bengal Health and LocalSelf-GovernmentDepartment. 2008.12.
124. Bruce Carleton. Post-Marketing Pharmacosurveillance In Canada. http://www.hc-sc.gc.ca/dhp-mps/index-eng.php, 2008.12.
125. Wendy Kennedy. The Health Transition Fund (Pharmaceutical Issues). http://www.hc-sc.gc.ca, 2008.12.
126. A Comparison of Pharmaceutical Reaseach and Development Spending. Patented Medicine Prices Review Board, http://www.mohfw.gov.bd/, 2008.12.
127. Access to Therapeutic Products in Canada, ministry of health. http://www.mohfw.gov.bd/, 2008.12.
128. National Pharmaceuticals Strategy (NPS). ministry of health. http://www.mohfw.gov.bd/, 2008.12.
129. Gary Fox, Medicines that Work for Canadians (Business Plan for a Drug Effectiveness and Safety Network). http://www.mohfw.gov.bd/, 2008.12.
130. Traditional and Complementary Medicine. http://www.myhealth.gov.my/myhealth/eng/ubat_anda_content.jsp?lang=ubat&storymaster=1225785083091&storyid=1225785618675&sub, 2008.12.
131. Medicines (Advertisement And Sale)Act, http://www.pharmacy.gov.my/, 2008.12.
132. Registration of Pharmacists Act, http://www.pharmacy.gov.my, 2008.
133. 马来西亚药品管理体系, http://www.pharmacy.gov.my. 2008.12.
134. Drug Registration Guidance Document, National Pharmaceutical Control Bureau, http://www.pharmacy.gov.my, 2008.
135. drug policy, http://www.nppaindia.nic.in/drug_pol86/txt1.html, 2008.
136. Drugs(Prices Control) Order. Ministry of Chemicals and Fertilizers. http://www.nppaindia.nic.in/drug_price95/txt1.html, 2008.12.
137. Modifications in Drug Policy. http://www.nppaindianic.in/drug_pol86/modif86/mod1.html, 2008.12.
138. Pharmaceutical Policy-2002. Prime Minister’s Advisory Council. http://www.nppaindia.nic.in/may-2002/policy-02.html, 2008.12.
139. Dte.GHS, Central Drugs Standard Control Organization-Laws Pertaining To Manufacture And Sale Of Drugs In India, Ministry of Health and Family Welfare. http://www.cdsco.nic.in/html/law.htm.
140. The Drugs And Cosmetics Act And Rules. Ministry of Health And Family Welfare. http://www.cdsco.nic.in/html/Copy%20of%201.%20D&CAct121.pdf, 2008.12.
141. Price Control Order (DPCO), National Pharmaceutical Pricing Authority . http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-policies/drugs-price-control-order.html, 2008.12.
142. Procedure for Price Fixation. National Pharmaceutical Pricing Authority, http://www.nppaindia.nic.in/may-2002/procedure-bd.html, 1 2008.12.
143. Procedure for Pricing of Formulations. National Pharmaceutical Pricing Authority. http://www.nppaindia.nic.in/may2002/procedure-form.html, 2008.12.
144. Central Drugs Standard Control Organization-Drugs Control Administration. Drugs Control Administration. http://www.cdsco.nic.in/html/Drugs_ContAd.html, 2008.12.
145. 中华人民共和国药品管理法, 国家食品药品监督管理局. http://www.sda.gov.cn/WS01/CL0064/23396.html, 2008.12.
146. 中华人民共和国药品管理法实施条例, 国家食品药品监督管理局. http://www.sda.gov.cn/WS01/CL0062/23395.html, 2008.12.
147. WHO. Essential medicines: access, quality and rational use – highlights of 2000, www.who.int/mip2001/files/2158/MIP01_APR_HTP2.en.pdf, 2008.12.
148. WHO. The WHO Essential Medicines List (EML): 30th anniversary. www.who.int/entity/medicines/events/fs/en/, 2008.12.
149. WHO. Comparative analysis of national drug policies. www.wpro.who.int/NR/rdonlyres/F1EFC301-FD5E-4BEE-9FD7-656965FD882B/0/EDMnewsletterECACPWHOyear2.pdf, 2008.12.
150. WHO Regional Office of the Western Pacific. Drug Price Control Bills in the Philippines/ Ethical Practices in Medicines Regulation and Procurement. Essential drug & medicine policy, 2008.12.
151. WHO. The Role of Education in the Rational Use of Medicines. www.wpro.who.int/NR/rdonlyres/8B64881B-DE1A-4A31-B670-B87265FBBB7F/0/EDMP_Dec04.pdf, 2008.12.
152. WHO. Malaysia formulates national medicines policy. Essential drug & medicine policy, 2002, 1(1):537-542.
153. WHO. Strengthening ADR Monitoring in the Philippines. Essential drug & medicine policy, 2003, 2(1): 765-769.
154. WHO. Computerized Drug Registration- The Lao People’s Democratic Republic/ Monitoring and Assessing the Pharmaceutical Situation in Malaysia. Essential drug & medicine policy, 2002, 1(2): 253-258.
155. WHO. Assessment of the Distribution Practices of Medicines in thePhilippines. Essential drug & medicine policy, 2004, 3(2): 753-760.
156. WHO. Philippines Chosen as a MeTA Pilot Country/ Cheaper Medicines Bill in the Philippines/ Philippines Develops Quality Seal System for Pharmaceuticals. Essential drug & medicine policy, 2007, 7(3): 341-346.
157. WHO. Medicines Price Monitoring in Malaysia. Essential drug & medicine policy, 2006, 5(1): 445-448.
158. WHO. Annual Report 2001:Essential Drugs and Medicines Policy: Extending the Evidence Base. www.who.int/mip2002/index.pl%3Fid=2304&isa=Item&field_name=item_attachment_file&op=download_file, 2008.12.
159. WHO. How to develop a national formulary based on the WHO model formulary. www.who.int/emlib/docs/National_MF_Manual2004-8.pdf, 2008.12.
160. WHO. Medicine Prices in Ghana: A comparative study of Public, Private and Mission sector medicine prices. www.afro.who.int/dsd/survey_reports/ghana.pdf, 2008.12.
161. WHO. Biregional Workshop On Promoting Ethical Practices In Medicines Registration And Procurement., whqlibdoc.who.int/wpro/2006/RS_2005_GE_12_MAA.pdf, 2008.12.
162. WHO. Essential drugs and other supplies. http://www.searo.who.int/EN/Section313/Section1515_6124.htm, 2008.12.
163. WHO. rational use of medicines in the lao people’s democratic republic strategy/ combating counterfeit drugs in the lao people’s democratic republic. Essential drug & medicine policy, 2003, 2(2): 752-756.
164. WHO. Drug Supply Management in the Context of IMCI（Drug Supply and Management Training in South Africa. whqlibdoc. who.int/searo/2001/SEA_Drugs_152.pdf, 2008.12.
165. WHO. Rational Drug Use (RDU). www.emro.who.int/Publications/EMHJ/1305/article25.htm, 2008.12.
166. WHO. Use of the WHO certification scheme on the quality of pharmaceutical products moving in international commerce. whqlibdoc.who.int/hq/1994/WHO_DAP_94.21.pdf, 2008.12.
167. WHO. Uganda pharmaceutical sector baseline survey. whqlibdoc.who.int/hq/2002/a87427_eng.pdf, 2008.12.
168. WHO. An assessment of the pharmaceutical sector. whqlibdoc.who.int/hq/2002/a87429_eng.pdf, 2008.12.
169. WHO. Effective drug regulation. www.who.int/entity/medicines/areas/rational_use/startingstrengdrugbulletin.pdf, 2008.12.
170. WHO. Reports World Medicines Situation. whqlibdoc.who.int/hq/1994/WHO_DAP_94.21.pdf, 2008.12.
171. WHO. Essential Medicines List. whqlibdoc.who.int/hq/2006/WHO_PSM_PAR_2006.5_eng.pdf, 2008.12.
172. WHO. Successful partnership in Pakistan for rational use and management of medicines. Essential Drugs in Brief, 2003, 3(9).
173. WHO. Access to affordable essential medicines. www.who.int/entity/medicines/mdg/MDG08ChapterEMedsEn.pdf, 2008.12.
174. WHO. Regional Strategy For Improving Access To Essential Medicines In The Western Pacific Region, 2004-2009, 2008.12.
175. Implementing Guidelines For The Philippines NDP System. Ministry of health. http://www.doh.gov.ph/ndp_issuances, 2008.12.
176. Lao national drug policy programme. Department for democracy and social development.http://www.globala.sida.se/sida/jsp/sida.jsp?d=118&a=2218&language=en_US, 2008.12.
177. Oman National Drug Policy. The Directorate General Of Pharmaceutical Affairs And Drug Control. http://www.moh.gov.om/pharma/ndpeng.pdf, 2008.12.
178. National medicine policy ( Australia ). Department of health and aging. http://www.health.gov.au/internet/main/publishing.nsf/Content/0241A32640D477CACA256F18004685E4/.
179. National drug policy (Bhutan). Department of Medical Services Ministry of Health Royal Government of Bhutan. http://www.health.gov.bt/downloads/drugPolicy.pdf, 2008.12.
180. National Drug Policy for South Africa. Minister of Health. http://www.doh.gov.za/docs/policy/drugsjan1996.pdf, 2008.12.
181. National Drug Policy (Nepal). Commitment of Government Of Nepal. http://www.google.cn/search?hl=zh-CN&newwindow=1&q=National+Drug+Policy+nepal&btnG= Google+%E6%90%9C%E7%B4%A2&meta= &aq=f&oq=, 2008.12.
182. National Medicinal Drug Policy For SriLanka, http://www.who.int/medicines/areas/policy/NMDP_SriLanka.pdf, 2008.12.
183. National drug policy (Pakistan). Ministry of health. http://www.dcomoh.gov.pk/publications/ndp.php, 2008.12.
184. National drug policy (Uganda). The National Drug Authority, http://www.nda.or.ug/index.php, 2008.12.
185. National Medicine Policy (Afghanistan). Ministry of Health. http://ispb.univ-lyon1.fr/Lyon%20Kaboul/politique_de_sante_en_afghanistan/rapports/Politique%20du%20m%E9dicament.pdf, 2008.12.
186. National Pharmaceuticals Strategy ( Canada ). Health Canada, http://www.hc-sc.gc.ca/hcs-sss/alt_formats/hpb-dgps/pdf/pubs/2006-nps-snpp/2006-nps-snpp-eng.pdf, 2008.12.
187. Ghana National Drug Policy. Ministry of Health (GNDP) Ghana, http://www.who.int/countries/gha/publications/Ghana_National_DrugPolicy_2nd_Edition.pdf, 2008.12.
188. National medicines policy of Malaysia. Ministry of health Malaysia. http://www.pharmacy.gov.my/, 2008.12.
189. National drug policy (Bangladesh) . Ministry Of Health And Family Welfare . http://www.ailonline.net/skf_new/images/files/.
190. National_Drug_Policy_May_05.pdf, 2008.12.
191. 张新平,李少丽. 药物政策学. 北京: 科学出版社, 2003.

Next Article
Use of GRADE grid to Reach Decisions on Clinical Practice Guidelines when Consensus is Elusive*

Chinese Journal of Evidence-Based Medicine

A Systematic Review of National Drug Policy in Seventeen Countries

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content